Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/29643
Title: Cost-effectiveness of genotype testing for primary resistance in Brazil
Authors: Luz, Paula M
Morris, Bethany L
Grinsztejn, Beatriz
Freedberg, Kenneth A
Veloso, Valdilea G
Walensky, Rochelle P
Losina, Elena
Nakamura, Yoriko M
Girouard, Michael P
Sax, Paul E
Struchiner, Claudio J
Paltiel, A. David
Affilliation: Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Division of General Medicine./ The Medical Practice Evaluation Center. USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Division of General Medicine./ The Medical Practice Evaluation Center. USA./ Massachusetts General Hospital. Division of Infectious Disease. Boston, MA, USA./ Harvard Medical School. Harvard University Center for AIDS Research. Boston, MA, USA./ Boston University School of Public Health. Department of Epidemiology. Boston, MA, USA./ Harvard School of Public Health. Department of Health Policy and Management. Boston, MA. USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Division of General Medicine./ The Medical Practice Evaluation Center. USA./ Massachusetts General Hospital. Division of Infectious Disease. Boston, MA, USA./ Harvard Medical School. Harvard University Center for AIDS Research. Boston, MA, USA./ Brigham and Women's Hospital. Department of Medicine. Division of Infectious Disease. Boston, MA, USA.
The Medical Practice Evaluation Center./ Brigham and Women's Hospital. Department of Orthopedic Surgery. Boston, MA, USA./ Boston University School of Public Health. Department of Biostatistics. Boston, MA, USA.
Division of General Medicine./ The Medical Practice Evaluation Center. USA.
Division of General Medicine./ The Medical Practice Evaluation Center. USA.
Harvard Medical School. Harvard University Center for AIDS Research. Boston, MA, USA./ Brigham and Women's Hospital. Department of Medicine. Division of Infectious Disease. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Yale School of Public Health. New Haven, CT, USA.
Abstract: HIV genotype-resistance testing can help identify more effective antiretroviral treatment (ART) regimens for patients, substantially increasing the likelihood of viral suppression and immune recovery. We sought to evaluate the cost-effectiveness of genotype-resistance testing before first-line ART initiation in Brazil.
Keywords: Genotype
Cost-effectiveness
Brazil
HIV
Drug resistance
Issue Date: 2015
Citation: LUZ, P. M. et al. Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. Journal of Acquired Immune Deficiency Syndromes, v. 68, n. 2, p. 152–161, 2015
DOI: 10.1097/QAI.0000000000000426
ISSN: 1525-4135
Copyright: restricted access
Appears in Collections:INI - Artigos de Periódicos



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.